



Maine State Legislature  
Joint Standing Committee on Health & Human Services  
210 State Street  
Augusta, ME 04333

March 12, 2026

Re: Support for LD 2196

Dear Committee Members,

On behalf of the Infusion Access Foundation, we urge you to support LD 2196 to protect patients from unnecessary delays and disruptions in accessing critical medical care. Patients who rely on infusion therapy and other essential treatments should not face repeated administrative barriers that interfere with their ability to receive consistent, medically necessary care.

The Infusion Access Foundation is a nonprofit advocacy organization dedicated to protecting access to infusions and injections. We support patients across all disease states and advocate for expanding access to the therapies that help patients live their best, healthiest lives. In conjunction with our grassroots advocacy work, we advocate for individual patients who face significant barriers to care.

Frequent prior authorization renewals, administrative burdens, and sudden coverage changes can delay care and disrupt treatment plans for patients with chronic, complex, and rare conditions who depend on ongoing therapy. LD 2196 offers practical solutions to help ensure patients receive the care they need without unnecessary interruptions.

This bill will:

- Ensure treatment stability by extending the validity of prior authorizations for services and diagnostic tests related to chronic conditions to one year, reducing the need for repeated approvals that burden patients.
- Reduce unnecessary administrative renewals by prohibiting insurers from requiring prior authorization renewals more than once every two years for treatments that are medically necessary for longer than one year.



# Infusion Access Foundation

- Protect patients when they change health plans by ensuring that previously approved services or prescriptions remain covered for at least 90 days during transitions, preventing disruptions in treatment.
- Provide advance notice of coverage changes by requiring insurers to give 90 days' notice before restricting coverage for previously approved services or medications, allowing patients time to coordinate care with their providers and maintain treatment continuity.

For patients managing chronic illnesses and complex conditions, timely access to treatment is not optional. No one should face interruptions in care due to administrative hurdles or insurance transitions. LD 2196 will help patients stay on track with their treatment plans, reduce delays, and improve overall health outcomes.

We ask you to support LD 2196 to help protect access to infusion therapy and ensure Maine's health care system works more effectively for patients who rely on consistent, lifesaving treatments.

Thank you for your time and consideration.

Sincerely,

Alicia Barron, LGSW  
Executive Director  
Infusion Access Foundation